Phlotonics is transforming drug discovery and biomanufacturing with cutting-edge photonic biosensing technology. Our real-time, multiplexed biosensors provide unparalleled precision in monitoring cellular activity, enabling faster, more accurate preclinical drug testing and bioprocess optimization. With a scalable “razor blade” business model, a strong IP portfolio, and strategic partnerships with BARDA, AIM Photonics, ARMI, and leading CROs, Phlotonics is well-positioned to capture a share of the $20 billion preclinical market. Backed by $23M in federal funding and aligned with regulatory shifts favoring human-based models over animal testing, we offer a high-growth investment opportunity in the future of precision medicine and regenerative manufacturing.